TG THERAPEUTICS, INC. TGTX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, TG THERAPEUTICS, INC. reported revenue across 6 products and services; the largest, Product, was $607M, 97.0% of the filed sum (+93.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$607M97.0%+93.5% yoy
- License$9.36M1.5%-38.7% yoy
- Royalty$5.62M0.9%+601.0% yoy
- Other Revenue$3.59M0.6%+97.0% yoy
- License Revenue$152K0.0%0.0% yoy
- Milestone$00.0%-100.0% yoy
Members sum to the consolidated $616M for this period.
- Product$201M96.5%+68.2% yoy
- License Revenue$3.61M1.7%+200.6% yoy
- License$3.61M1.7%+200.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.